GoAI
Get started
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc.

TVRD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.86

+$0.03 · +1.64%

Aug 21, 4:00 PM ET

TVRD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

24

Expensive

Momentum

42

Neutral

Sentiment

68

Bullish

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $1.86

52-week range

Current $1.86

Open
$1.83
Previous close
$1.83
Volume
166.83K
Market cap
17.45M USD
50-day average
$2.4154
-22.99% below average
200-day average
$3.4379
-45.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
11.37M USD
P/E (TTM)
-0.67×
P/B (TTM)
2.08×
P/S (TTM)
0×
EV / EBITDA
-0.63×
Earnings yield
-57.09%
Free cash flow yield
-73.66%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-86.96%
Return on assets
-56.79%
Return on invested capital
-126.49%

Financial health

Debt / equity
0.02×
Current ratio
2.86×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends202%-233%-667%-1102%Gross margin, FY2021: 93.25%Gross margin, FY2022: 82.05%Gross margin, FY2023: 69.32%Gross margin, FY2024: 88.62%Operating margin, FY2021: -386.85%Operating margin, FY2022: -209.08%Operating margin, FY2023: -579.43%Operating margin, FY2024: -781.57%Net margin, FY2021: -384.06%Net margin, FY2022: -204.16%Net margin, FY2023: -565.21%Net margin, FY2024: -992.95%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 93.25%. Gross margin FY2022 82.05%. Gross margin FY2023 69.32%. Gross margin FY2024 88.62%. Operating margin FY2021 -386.85%. Operating margin FY2022 -209.08%. Operating margin FY2023 -579.43%. Operating margin FY2024 -781.57%. Net margin FY2021 -384.06%. Net margin FY2022 -204.16%. Net margin FY2023 -565.21%. Net margin FY2024 -992.95%.

Income trends

Revenue

7.14M USD-65.96%

Operating income

−26.75M USD+52.05%

Net income

−18.21M USD+74.30%
Income trends across reported periods58.2M USD−7.14M USD−72.49M USD−137.83M USDRevenue, FY2021: 23.03M USDRevenue, FY2022: 41.87M USDRevenue, FY2023: 20.97M USDRevenue, FY2024: 7.14M USDOperating income, FY2021: −89.08M USDOperating income, FY2022: −87.54M USDOperating income, FY2023: −121.5M USDOperating income, FY2024: −55.78M USDOperating income, FY2025: −26.75M USDNet income, FY2021: −88.44M USDNet income, FY2022: −85.47M USDNet income, FY2023: −118.51M USDNet income, FY2024: −70.87M USDNet income, FY2025: −18.21M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 23.03M USD. Revenue FY2022 41.87M USD. Revenue FY2023 20.97M USD. Revenue FY2024 7.14M USD. Operating income FY2021 −89.08M USD. Operating income FY2022 −87.54M USD. Operating income FY2023 −121.5M USD. Operating income FY2024 −55.78M USD. Operating income FY2025 −26.75M USD. Net income FY2021 −88.44M USD. Net income FY2022 −85.47M USD. Net income FY2023 −118.51M USD. Net income FY2024 −70.87M USD. Net income FY2025 −18.21M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—7.14M USD20.97M USD41.87M USD23.03M USD
Cost of goods sold95K USD812K USD6.43M USD7.51M USD1.55M USD
Gross profit−95K USD6.33M USD14.54M USD34.35M USD21.47M USD
Research and development18.01M USD32.76M USD108.38M USD91.76M USD82.58M USD
Selling, general, and administrative8.74M USD26.39M USD27.65M USD30.13M USD27.98M USD
Operating expenses26.75M USD62.11M USD136.03M USD121.89M USD110.56M USD
Interest income1.38M USD2.83M USD1.32M USD654K USD603K USD
Interest expense—8.47M USD—3K USD—
Depreciation and amortization95K USD192K USD259K USD1.67M USD1.55M USD
Operating income−26.75M USD−55.78M USD−121.5M USD−87.54M USD−89.08M USD
Net income−18.21M USD−70.87M USD−118.51M USD−85.47M USD−88.44M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-54.06%
11 comparable reports
Latest EPS result
-0.69
Estimate -0.7 · Beat by 2.05%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.43-2.82-5.21-7.61Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -1.68, estimate -7.08, surprise +76.27%, Beat. Q2 2025, reported May 13, 2025: actual -3.22, estimate -0.585, surprise -450.43%, Miss. Q3 2025, reported Aug 14, 2025: actual -1, estimate -0.51, surprise -96.08%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.59, estimate -0.83, surprise +28.92%, Beat. Q1 2026, reported Mar 31, 2026: actual -0.78, estimate -0.55, surprise -41.82%, Miss. Q2 2026, reported May 8, 2026: actual -0.73, estimate -0.65, surprise -12.31%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.69, estimate -0.704, surprise +2.05%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.558, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates10.08M7.05M4.03M999.6KQ1 '24MissQ2 '24BeatQ3 '24EstimateQ4 '24EstimateQ1 '25EstimateQ2 '25No estimate
Q1 2024, reported Mar 4, 2024: actual 3M USD, estimate 9.42M USD, surprise -68.12%, Miss. Q2 2024, reported May 13, 2024: actual 2.14M USD, estimate 1.68M USD, surprise +26.80%, Beat. Q3 2024, reported Aug 14, 2024: actual —, estimate 1.18M USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 14, 2024: actual —, estimate 2.02M USD, surprise —, Comparison unavailable. Q1 2025, reported Mar 11, 2025: actual —, estimate 1.69M USD, surprise —, Comparison unavailable. Q2 2025, reported May 13, 2025: actual 2.57M USD, estimate —, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.75

370.43% upside
Past 12 months12-month forecastHigh $13.00Average $8.75Low $3.00

TVRD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TVRD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
542.69K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
180.51K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research TVRD

research.disclaimer